Short Courses

Sunday, April 7

Morning, 10:00 am - 1:00 pm

SC1: Preclinical and Clinical Assessment of Immunogenicity: Focus on New Modalities Including Bi- and Tri-Specific Antibodies, Oligonucleotides, Gene Therapy and CAR T

Darshana Jani, MSc, Associate Director, Global Lead Biologics, Clinical Assay Group, Global Product Development, Pfizer, Inc.

Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU) 

Rama Boyanapalli, PhD, Associate Director, Bioanalytical and Biomarker Development, Wave Life Sciences 

Linzhi Chen, PhD, Senior Research Fellow & Bioanalytical Group Leader, Boehringer Ingelheim Pharmaceuticals

SC2: Translational Biotherapeutic Development Strategies Part 1: Discovery, Molecular Assessment and Early Stage Development

Juan Carlos Almagro, PhD, Founder and Director, GlobalBio, Inc.

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.

SC3: Selection, Screening and Engineering for Affinity Reagents

Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)

Christian Kunz, PhD, Director, MorphoSys AG

SC4: Understanding and Modulating Tumor Microenvironment for Immunotherapy

David A. Eavarone, PhD, Associate Principal Scientist, Harbour Biomed

Afternoon, 2:30 - 5:30 pm

SC5: In silico Immunogenicity Predictions (Hands-On) Workshop

Vinodh B. Kurella, PhD, Principal Scientist, Protein Engineering, Merrimack Pharmaceuticals

Daron Forman, PhD, Principal Scientist, Molecular Discovery Technologies, Bristol-Myers Squibb

SC6: Introduction to Host Cell Proteins: Analysis, Characterization, Risks, and Requirements

Denise Krawitz, PhD, Principal Consultant, CMC Paradigms LLC

SC7: Translational Biotherapeutic Development Strategies Part 2: Analytical and Clinical Considerations

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Scott L. Klakamp, PhD, Senior Director & Head, Biophysics, Biologics Development Sciences, Janssen BioTherapeutics

Liming Liu, PhD, Senior Principal Scientist, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Merck Research Laboratories

An Song, PhD, Senior Vice President, Development Sciences, Immune-Onc Therapeutics, Inc.

SC8: Gene Therapy Products: Phase-Appropriate Analytical Development Strategies

Francis Poulin, PhD, Director, Analytical Development, Sanofi

Claire Davies, PhD, Associate Vice President, Bioanalytics, Sanofi

Tuesday, April 9

DINNER, 6:00 - 8:30 pm

SC9: Introduction to Biophysical Analysis for Biotherapeutics: Development Applications

Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi

SC10: CAR T-Cell Therapy for Solid Tumors

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School

Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College

Tara Arvedson, PhD, Director, Oncology Research, Amgen

SC11: Developability of Bispecific Antibodies: Formats and Applications

Nimish Gera, PhD, Director, Research and Development, Mythic Therapeutics

Thursday, April 11

dinner, 5:45 - 8:15 pm

SC12: Design Strategies and Development of ADCs

Robert Lutz, PhD, Principal Consultant, Crescendo Biopharma Consulting

SC13: Bioassay Quality by Design

Thomas Little, PhD, President and CEO, Bioassay Sciences, Thomas A. Little Consulting

SC14: Subvisible Protein Particles in Immunogenicity: Measurement, Characterization and Impact

Björn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG

Antonio Iglesias, PhD, Expert Scientist, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd. Basel

dINNER, 5:45 - 8:45 pm

SC15: Transient Protein Production in Mammalian Cells

Richard Altman, MS, Scientist, Protein Technologies, Amgen

Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

* Separate Registration Required.

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Sponsor updated
Sponsor updated
Sponsor updated
Agenda,Speaker,Sponsor updated
Sponsor updated

Premier Sponsors

View By: